Cambridge Innovation Capital (CIC), a leading venture capital firm investing in deep tech and life sciences, today announces that its portfolio company, CMR Surgical (CMR), has formed a strategic alliance with Stryker (NYSE: SYK), one of the world’s leading medical technology companies, with a market capitalisation of more than $100 billion.

Under the terms of the agreement, Stryker will make a $400 million (£300 million) preferred equity investment in CMR Surgical to support future innovation and global commercialisation of the Versius portfolio, subject to customary closing conditions. The preferred equity investment grants Stryker an exclusive option to acquire 100% of CMR Surgical’s outstanding equity in the future, subject to the agreement’s terms. Stryker will also serve as the exclusive US sales agent for the Versius portfolio.

Entering the US market is a critical commercial inflection point for CMR. Stryker will bring the necessary scale, deep customer relationships, commercial execution and proven track record of bringing innovative technologies to market, to accelerate Versius’s expansion across the region.

A UK technology success story

Versius is the second most widely used soft-tissue surgical robot in the world. It has been used in more than 50,000 operations in more than 35 countries across Europe, Asia Pacific, Latin America, the Middle East, Africa and Australia. In the UK, CMR partners with more than 20 NHS trusts, including Addenbrooke’s, Guy’s and St Thomas’ in London and Manchester Royal Infirmary.

CMR Surgical will continue to lead portfolio development and commercialisation in markets outside of the US. This R&D will remain in Cambridge, and manufacturing will continue at CMR’s Ely facility.

Backing CMR from prototype to global scale

CIC was the first institutional investor in CMR when the company had an early prototype. Recognising that existing robotic systems were cost-prohibitive and inflexible – resulting in fewer than 3% of suitable procedures being performed robotically – the founders set out to develop a modular, highly adaptable and accessible surgical platform designed to broaden patient access.

CIC Partner, Robert Tansley, a former surgeon, immediately understood the clinical utility of CMR. That understanding gave CIC the conviction to become CMR’s first institutional investor. Since then, CIC has invested in every CMR funding round, most recently from its Opportunity Fund, which supports high-growth UK science and technology enterprises through their scale-up phase.

Stryker’s strategic investment serves as robust external validation of the technology, the leadership team and the core investment thesis in which CIC first invested.

Andrew Williamson, Managing Partner at Cambridge Innovation Capital, said: “Stryker’s decision to invest $400 million into CMR Surgical represents a UK manufacturing and technology success story. It will allow one of Britain’s breakout medical technology businesses to expand at scale and pace in America, by far the world’s biggest healthcare market, as well as increase its global sales in Asia and Europe.

“The deal gives CMR the backing to supercharge its global growth, while reinforcing its UK foundations, with IP, R&D, jobs, infrastructure and manufacturing remaining and scaling here. As CMR’s first institutional investor, we are proud to have backed the team since it produced the first prototype of a surgical robot. The company has proven what can be achieved by UK science and technology businesses when they have global ambitions and the long-term backing they need to scale.”

Andy Pierce, Group President, Medsurg and Neurotechnology, Stryke, said: “Soft-tissue robotics is a high-growth adjacency and a natural extension of Stryker’s strengths in endoscopy, visualization and enabling technologies. We have evaluated the segment carefully for years, and this alliance represents a thoughtful and disciplined entry that combines the complementary strengths of both companies. We selected CMR Surgical and the Versius portfolio because of the opportunity to help healthcare providers grow robotic-assisted surgery adoption across a broad range of procedures in hospitals and ASCs.”

Massimiliano Colella, Chief Executive Officer of CMR Surgical, said: “This strategic alliance is a significant milestone for CMR and a strong endorsement of the technology, clinical experience and global business we have built. Stryker’s investment will give us additional strength to accelerate innovation and the continued global expansion of the Versius portfolio, while its scale and deep customer relationships create a significant growth opportunity in the United States. We also look forward to welcoming Andy Pierce to our board of directors and benefiting from his more than 30 years of MedTech leadership experience at Stryker as we continue expanding access to robotic-assisted surgery globally.”